Evidence map›Paper›PMID 25424399›Full record

Trial reportRadiation oncology (London, England)2014

Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.

Alysa Fairchild, Johannes A Langendijk, Sandra Nuyts, Christopher Scrase, Milan Tomsej, Danny Schuring, Akos Gulyban, Sunita Ghosh, Damien C Weber, Wilfried Budach

Open access · goldAbstract readClinical Trial, Phase II
In one paragraph

Trial report in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 6 countries.

Alysa FairchildDepartment of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, T6G 1Z2, Edmonton, AB, Canada. alysa@ualberta.ca.
Johannes A LangendijkDepartment of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. j.a.langendijk@umcg.nl.
Sandra NuytsDepartment of Radiation Oncology, University Hospital Leuven, KU Leuven, Leuven, Belgium. Sandra.nuyts@uzleuven.be.
Christopher ScraseDepartment of Radiation Oncology, Ipswich Hospital, Ipswich, UK. Christopher.scrase@ipswichhospital.nhs.uk.
Milan TomsejDepartment of Radiotherapy, CHU Charleroi, Charleroi, Belgium. tomsej@chu-charleroi.be.
Danny SchuringDepartment of Radiotherapy, Catharina Hospital, Eindhoven, The Netherlands. danny.schuring@catharinaziekenhuis.nl.
Akos GulybanDepartment of Radiation Oncology, University Hospital of Liege, Liege, Belgium. akos.gulyban@gmail.com.
Sunita GhoshDepartment of Experimental Oncology, Cross Cancer Institute, Edmonton, Canada. sunitaghosh@albertahealthservices.ca.
Damien C WeberEORTC Quality Assurance in Radiotherapy Team, Brussels, Belgium. damien.weber@psi.ch.
Wilfried BudachDepartment of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany. wilfried.budach@med.uni-duesseldorf.de.
Canadian Cancer Society · CAGrand Charleroi Hospital · BEHeinrich Heine University Düsseldorf · DEIpswich Hospital · GBKU Leuven · BEPaul Scherrer Institute · CHRadboud University Nijmegen · NLUniversity Medical Center Groningen · NLUniversity of Alberta · CAUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe phase III 22071-26071 trial was designed to evaluate the addition of panitumumab to adjuvant chemotherapy plus intensity modulated radiotherapy (IMRT) in locally advanced resected squamous cell head and neck cancer. We report the results of the dummy run (DR) performed to detect deviations from protocol guidelines. METHODS AND MATERIALS: DR datasets consisting of target volumes, organs at risk (OAR) and treatment plans were digitally uploaded, then compared with reference contours and protocol guidelines by six central reviewers. Summary statistics and analyses of potential correlations between delineations and plan characteristics were performed.

resultsOf 23 datasets, 20 (87.0%) GTVs were evaluated as acceptable/borderline, along with 13 (56.5%) CTVs and 10 (43.5%) PTVs. All PTV dose requirements were met by 73.9% of cases. Dose constraints were met for 65.2-100% of mandatory OARs. Statistically significant correlations were observed between the subjective acceptability of contours and the ability to meet dose constraints for all OARs (p ≤ 0.01) except for the parotids and spinal cord. Ipsilateral parotid doses correlated significantly with CTV and PTV volumes (p ≤ 0.05).

conclusionsThe observed wide variations in treatment planning, despite strict guidelines, confirms the complexity of development and quality assurance of IMRT-based multicentre studies for head and neck cancer.

Indexed as

Guideline AdherenceAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellChemoradiotherapyHead and Neck NeoplasmsHumansOrgans at RiskPanitumumabPractice Guidelines as TopicProspective StudiesQuality Assurance, Health CareRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedSquamous Cell Carcinoma of Head and NeckAntibodies, MonoclonalPanitumumab

Identifiers

PMID25424399
PMCPMC4311463
OpenAlexW2113417445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.